Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Exdensur Coverage Criteria Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0787

    Exdensur

    Customize your policy alerts

    Sign up for Cigna Policy IP0787 alerts

    Get alerted when Policy IP0787 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and benefit coverage for Exdensur (depemokimab-ulaa) subcutaneous injection in adults and pediatric patients aged 12 years and older with severe eosinophilic asthma, subject to clinical, specialist, preferred-product, continuation, dosing, and coding criteria.

    Policy Summary
    PayerCigna
    PolicyExdensur
    Policy CodePolicy IP0787
    Change TypeModified
    Effective DateNovember 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and ensure initial prescribing is by, or in consultation with, an allergist, immunologist, or pulmonologist.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code J2361 for injection of depemokimab-ulaa, 1 mg, was added to the coding information.

    Descriptions for HCPCS codes C9399, J3490, and J3590 were updated in the coding information.

    ≥12 yearsMinimum age
    ≥150 cells/µLEosinophil threshold
    6 monthsInitial approval
    1 yearContinuation approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    100 mg q6 months
    Dose
    J2361Added HCPCS code

    Coverage Criteria

    Asthma Initial and Continuation Therapy

    Approve Exdensur for asthma for the duration specified when the patient meets ONE of the following pathways:

    ONE of the following pathways

    • Initial Therapy — approve for 6 months

      • Patient is ≥ 12 years of age.
      • ONE of the following

        • Patient has a blood eosinophil level ≥ 150 cells per microliter within the previous 6 weeks.
        • Patient had a blood eosinophil level ≥ 150 cells per microliter before treatment with Exdensur or another monoclonal antibody therapy that may alter blood eosinophil levels.

          Examples include Exdensur, Adbry (tralokinumab-ldrm), Cinqair (reslizumab), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Fasenra (benralizumab), Nemluvio (nemolizumab-ilto), Nucala (mepolizumab), Tezspire (tezepelumab-ekko), and Xolair (omalizumab).

      • At least 3 consecutive months of combination therapy with BOTH of the following

        • An inhaled medium- or high-dose corticosteroid.
        • At least one additional asthma controller or asthma maintenance medication.

          Examples include inhaled long-acting beta2-agonists, inhaled long-acting muscarinic antagonists, and monoclonal antibody therapies for asthma. A combination inhaler containing an inhaled corticosteroid and additional asthma controller or maintenance medication fulfills both requirements.

      • ONE of the following history criteria

        • ALL of the following

          • Forced expiratory volume in 1 second (FEV1) is <80% predicted.

            The reduced FEV1 should not be due to smoking-related chronic obstructive pulmonary disease.

          • FEV1/forced vital capacity (FVC) is <0.80.
        • ONE of the following

          • Increase of ≥ 12% and ≥ 200 mL in FEV1 following administration of a standard dose of a short-acting bronchodilator.
          • Increase of ≥ 12% and ≥ 200 mL in FEV1 between prescriber visits.
          • Increase of ≥ 12% and ≥ 200 mL in FEV1 from baseline to after at least 4 weeks of asthma treatment.
      • Asthma is uncontrolled or was uncontrolled at baseline — ONE of the following

        • Patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year.
        • Patient experienced one or more asthma exacerbations requiring hospitalization, an emergency department visit, or an urgent care visit in the previous year.
        • Patient's asthma worsens upon tapering oral (systemic) corticosteroid therapy.
      • Medication is prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
      • Preferred product criteria are met for the product(s) listed in the applicable table(s).
    • Continuation Therapy — approve for 1 year

      • Patient has already received at least 6 months of therapy with Exdensur.

        A patient who has received less than 6 months of therapy or is restarting Exdensur should be evaluated under Initial Therapy.

      • Patient continues to receive one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler.
      • According to the prescriber, the patient has responded to therapy.

        Examples of response include decreased asthma exacerbations, decreased asthma symptoms, decreased hospitalizations or emergency department, urgent care, or medical clinic visits due to asthma, and decreased requirement for oral corticosteroid therapy.

    Dosing

    Approve up to the following dose when the applicable asthma coverage criteria are met:

    Exdensur 100 mg administered subcutaneously once every 6 months.

    Exdensur is not indicated for the relief of acute bronchospasm or status asthmaticus.

    Concurrent use of Exdensur with another monoclonal antibody therapy is not covered. The efficacy and safety of Exdensur used in combination with other monoclonal antibody therapies have not been established. Monoclonal antibody therapies include Adbry (tralokinumab-ldrm), Cinqair (reslizumab), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Fasenra (benralizumab), Nemluvio (nemolizumab-ilto), Nucala (mepolizumab), Tezspire (tezepelumab-ekko), and Xolair (omalizumab).

    Uses outside the covered FDA-approved severe eosinophilic asthma indication and the applicable coverage criteria are not covered.

    Concurrent use of Exdensur with another monoclonal antibody therapy is not medically necessary.

    Any other use of Exdensur is not medically necessary, including uses not addressed by the covered severe eosinophilic asthma indication and criteria. This list may not be all-inclusive; criteria will be updated as new published data become available.

    Coding Information

    HCPCS CodesHCPCSCovered
    C9399Unclassified drugs or biologicals
    J2361Injection, depemokimab-ulaa, 1 mg
    J3490Unclassified drugs
    J3590Unclassified biologics
    HCPCS Codes considered medically necessary when applicable policy criteria are metHCPCSCovered
    C9399Unclassified drugs or biologicals (Code effective until 6 /3 0.
    J2361Injection, depemokimab-ulaa, 1 mg.
    J3490Unclassified drugs (Code effective until 6 /3 0 /202.
    J3590Unclassified biologics (Code effective until 6 /3 0 /202 6)
    Blood eosinophil level
    Current eosinophil thresholdBlood eosinophil level ≥150 cells per microliter
    Current-result timingMeasured within the previous 6 weeks
    Prior qualifying resultA level ≥150 cells per microliter before treatment with Exdensur or another monoclonal antibody therapy that may alter eosinophil levels also qualifies
    FEV1
    FEV1 thresholdFEV1 <80% predicted
    Required contextThe reduced FEV1 must not be due to smoking-related chronic obstructive pulmonary disease

    Provider Actions

    Prior Authorization

    Prior Authorization and Specialist Involvement

    Prior authorization is required for Exdensur. Initial approval requires the medication to be prescribed by, or used in consultation with, an allergist, immunologist, or pulmonologist because of the specialized evaluation, diagnosis, and monitoring required.

    Step Therapy

    Employer Plan Preferred Products

    For employer plans, initial Exdensur therapy requires documented trials of both Nucala and Fasenra. These products may require prior authorization.

    • Initial therapy applies to patients age 12 years and older.
    • A patient already started on Exdensur may meet the alternative preferred-product pathway.
    Step Therapy

    Individual and Family Plan Preferred Products

    Background

    Exdensur is an interleukin-5 antagonist monoclonal antibody used as add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adults and pediatric patients 12 years of age and older.

    Definitions

    Severe asthma
    Core definitionAsthma requiring high-dose inhaled corticosteroid treatment plus a second controller medication and/or systemic corticosteroids to prevent it from becoming uncontrolled
    Persistent diseaseAsthma that remains uncontrolled despite high-dose inhaled corticosteroid therapy plus the additional treatment also meets the definition
    Treatment contextThe second controller medication may be used with high-dose inhaled corticosteroid therapy, with systemic corticosteroids used when applicable
    Uncontrolled asthma
    Steroid-taper worseningAsthma that worsens when high-dose inhaled corticosteroids or systemic corticosteroids are tapered
    Poor symptom controlAsthma Control Questionnaire consistently ≥1.5 or Asthma Control Test <20

    Initial Therapy

    Continuation Therapy

    Currently Receiving Exdensur

    Approve for 1 year when all continuation criteria are met.

    Continuation therapy

    • Prior Exdensur therapy: Patient has already received at least 6 months of therapy with Exdensur.≥6 months

      A patient who has received less than 6 months of therapy or who is restarting therapy is evaluated under initial therapy.

    • Ongoing controller therapy: Patient continues to receive one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler.
    • Clinical response: According to the prescriber, the patient has responded to Exdensur therapy.

    Preferred-Product Requirements

    StepPlan typeProductRequirement
    1EmployerExdensur (depemokimab-ulaa subcutaneous injection)For initial therapy in patients aged 12 years or older, the patient must have tried both Nucala and Fasenra. Either product may require prior authorization.
    StepPlan typeProductRequirement
    1Individual and family plansExdensur (depemokimab-ulaa subcutaneous injection)For initial therapy in patients aged 12 years or older, the patient must have tried both Nucala Vial and Fasenra Syringes. Other Nucala and Fasenra dosage forms count toward this requirement; either product may require prior authorization.

    Quantity Limits

    Exdensur
    Dose100 mg
    FrequencyOnce every 6 months
    AdministrationGiven subcutaneously by a healthcare provider

    Administration Site

    Note

    Administer Exdensur in the provider office

    Exdensur should be administered by a healthcare provider by subcutaneous injection. The recommended dosage is 100 mg once every 6 months.

    Policy Summary
    PayerCigna
    PolicyExdensur
    Policy CodePolicy IP0787
    Change TypeModified
    Effective DateNovember 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and ensure initial prescribing is by, or in consultation with, an allergist, immunologist, or pulmonologist.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider ActionsBackgroundDefinitionsInitial TherapyContinuation TherapyPreferred-Product RequirementsQuantity LimitsAdministration Site
  1. Positive exercise challenge testing.
  2. Positive bronchial challenge testing.
  3. Pulmonary-function pathway
    The FEV1 threshold is used with FEV1/FVC <0.80 as one qualifying pulmonary-function pathway
    FEV1/FVC
    FEV1/FVC thresholdFEV1/FVC <0.80
    Required pairingThe ratio threshold is paired with FEV1 <80% predicted
    Alternative pathwayA qualifying bronchodilator, between-visit, treatment, exercise-challenge, or bronchial-challenge finding may satisfy the alternative airway-responsiveness pathway
    Bronchodilator or treatment response
    Required FEV1 improvementIncrease of ≥12% and ≥200 mL in FEV1
    After bronchodilatorThe increase may occur after administration of a standard dose of a short-acting bronchodilator
    Between visits or treatmentThe increase may occur between prescriber visits or from baseline after at least 4 weeks of asthma treatment
    Systemic corticosteroid exacerbations
    Qualifying frequencyTwo or more asthma exacerbations
    Required treatmentEach qualifying exacerbation required treatment with systemic corticosteroids
    Look-back periodThe exacerbations occurred in the previous year
    Asthma-related acute care
    Qualifying frequencyOne or more asthma exacerbations
    HospitalizationAn exacerbation requiring hospitalization qualifies
    Other acute-care settingsAn exacerbation requiring an emergency department visit or urgent care visit also qualifies

    For individual and family plans, initial Exdensur therapy requires documented trials of both Nucala Vial and Fasenra Syringes. Other Nucala or Fasenra dosage forms also count toward the respective trial requirement, and the products may require prior authorization.

    • Initial therapy applies to patients age 12 years and older.
    • A patient already started on Exdensur may meet the alternative preferred-product pathway.
    Documentation Required

    Initial and Continuation Clinical Documentation

    Submit clinical documentation supporting the applicable initial- or continuation-therapy criteria for review. Documentation should establish the patient's age, eosinophil history, controller-treatment history, objective asthma findings, uncontrolled disease history, specialist involvement, preferred-product requirements, and ongoing inhaled corticosteroid therapy when applicable.

    • Initial therapy: document age 12 years or older; blood eosinophil level of at least 150 cells per microliter within the previous 6 weeks or before therapy that may alter eosinophil levels; at least 3 consecutive months of an inhaled medium- or high-dose corticosteroid plus an additional controller or maintenance medication; qualifying pulmonary-function, bronchodilator, exercise-challenge, or bronchial-challenge findings; and uncontrolled asthma or baseline uncontrolled asthma.
    • Continuation therapy: document at least 6 months of Exdensur therapy and continued treatment with an inhaled corticosteroid or inhaled corticosteroid-containing combination inhaler.
    • For patients restarting Exdensur or with less than 6 months of therapy, submit documentation under the initial-therapy criteria.
    Documentation Required

    Document Response to Therapy

    For continuation approval, the prescriber must attest that the patient has responded to Exdensur therapy and provide evidence supporting that response.

    • Examples include decreased asthma exacerbations or symptoms; fewer hospital, emergency department, urgent care, or medical clinic visits; and reduced need for oral corticosteroid therapy.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Noncovered Diagnosis or Coding

    Reimbursement may be denied when Exdensur is billed for a diagnosis or condition not covered by the policy, or when the claim does not include an applicable covered code. Use the most appropriate code effective on the submission date and verify that codes have not been deleted or become ineligible.

    • Covered HCPCS codes listed in the policy include C9399, J2361, J3490, and J3590, subject to the policy criteria and code effective dates.
    • Exdensur for uses other than the covered severe eosinophilic asthma indication is considered not medically necessary.
    Severe exacerbation or airflow criteriaThe definition also includes two or more systemic corticosteroid bursts in the previous year, at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year, or FEV1 <80% predicted after appropriate bronchodilator withholding
    Baseline
    DefinitionThe period before receiving Exdensur or another monoclonal antibody therapy for asthma
    Applicable therapiesThe comparison includes prior asthma monoclonal antibody therapy such as Exdensur, Fasenra, Nucala, Tezspire, or Xolair
    Use in assessmentBaseline status is used when evaluating whether asthma was uncontrolled before Exdensur or another monoclonal antibody therapy

    Examples include decreased asthma exacerbations, decreased asthma symptoms, decreased asthma-related hospital, emergency department, urgent care, or medical clinic visits, or decreased requirement for oral corticosteroid therapy.